Evolution of the Average Target: Biogen Inc.

Evolution of the Target Price: Biogen Inc.

Changes in Analyst Recommendations: Biogen Inc.

9119fe4970d4813a20b80a2b48.uSzVmWxxhlsrT34N0jBFYHWcStVltFb2TJHp9nB_A9s.6gGUxi0usShfFjtMqGkBBxTPOb0K6yaeL_nQuhsoc5zXRLagDULuD28NTg~036c0c18d9545a3beabe551c81225629
06:32pm Mizuho Adjusts Price Target on Biogen to $241 From $221 MT
07-30 BMO Capital Adjusts Price Target on Biogen to $208 From $196, Maintains Market Perform Rating MT
07-30 TD Cowen Adjusts Price Target on Biogen to $225 From $215, Maintains Buy Rating MT
07-30 Canaccord Genuity Adjusts Price Target on Biogen to $248 From $245, Maintains Buy Rating MT
07-30 Goldman Sachs Adjusts Price Target on Biogen to $290 From $271, Maintains Buy Rating MT
07-30 BMO Raises Price Target on Biogen to $208 From $196, Keeps Market Perform Rating MT
07-30 UBS Adjusts Price Target on Biogen to $240 From $225, Maintains Buy Rating MT
07-30 RBC Trims Price Target on Biogen to $240 From $242, Keeps Outperform Rating MT
07-29 JPMorgan Lifts Biogen Price Target to $210 From $185 MT
07-29 Wedbush Adjusts Biogen Price Target to $215 From $201, Maintains Neutral Rating MT
07-29 Stifel Nicolaus Adjusts Biogen Price Target to $242 From $214 MT
07-28 Barclays Adjusts Biogen Price Target to $200 From $185, Maintains Equalweight Rating MT
07-24 Rothschild & Co Redburn Adjusts Price Target on Biogen to $210 From $190, Maintains Neutral Rating MT
07-21 BofA Securities Adjusts Biogen Price Target to $215 From $217 MT
07-21 Guggenheim Adjusts Price Target on Biogen to $280 From $260, Maintains Buy Rating MT
07-20 Goldman Sachs Adjusts Price Target on Biogen to $271 From $250, Maintains Buy Rating MT
07-14 Cantor Fitzgerald Adjusts Biogen Price Target to $237 From $206 MT
07-13 Wedbush Raises Price Target on Biogen to $201 From $196, Keeps Neutral Rating MT
07-13 Analyst recommendations: Biogen, Deckers Outdoor, Fortinet, Marathon Petroleum, UnitedHealth… Zonebourse
07-08 BofA Securities Adjusts Biogen Price Target to $217 From $203 MT
07-08 Morgan Stanley Adjusts Price Target Biogen to $222 From $224, Maintains Equalweight Rating MT
07-07 RBC Capital Adjusts Biogen Price Target to $242 From $227, Maintains Outperform Rating MT
07-07 Jefferies Adjusts Price Target on Biogen to $255 From $210 MT
07-07 Analyst recommendations: Ferguson, Medpace, Biogen, Crowdstrike, Take-Two… Zonebourse
07-06 HSBC Adjusts Price Target on Biogen to $157 From $150 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
- - - -
+9.3%
+29.35%
+33.03%
+12.87%
+2.88%
-7.93%
+35.79%
+6%
+31.42%
Average +16.97%
Weighted average by Cap. +17.40%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
36
Last Close Price
202.95USD
Average target price
234.35USD
Spread / Average Target
+15.47%
High Price Target
300.00USD
Spread / Highest target
+47.82%
Low Price Target
157.00USD
Spread / Lowest Target
-22.64%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

TD Cowen
Canaccord Genuity
Goldman Sachs
BMO Capital
UBS
RBC Capital Markets
JPMorgan Chase
Wedbush
Stifel Nicolaus
Barclays
Rothschild & Co Redburn
BofA Securities
Guggenheim
Cantor Fitzgerald
Morgan Stanley
Jefferies & Co.
HSBC
Needham & Co.
Mizuho Securities
Piper Sandler
Oppenheimer
Citigroup
Bernstein
Wells Fargo Securities
HC Wainwright
Baird
Truist Securities
Argus
Scotiabank
Redburn Atlantic
Leerink Partners
Raymond James
Atlantic Equities
Cowen
SVB Securities LLC
SVB Leerink
William Blair & Co.
Credit Suisse
DZ Bank
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
36
Last Close Price
202.95USD
Average target price
234.35USD
Spread / Average Target
+15.47%

Quarterly revenue - Rate of surprise